Sarah D Busslinger

Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer

F. Borgna, R. Schibli, P. Bernhardt, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer

F. Borgna, R. Schibli, P. Bernhardt, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.

R. Schibli, C. Müller, M. Benešová, 2022, Molecular pharmaceutics.

[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617

R. Schibli, C. Müller, Z. Talip, 2022, Cancers.

Inductively Coupled Plasma Mass Spectrometry─A Valid Method for the Characterization of Metal Conjugates in View of the Development of Radiopharmaceuticals.

R. Schibli, C. Müller, P. Schindler, 2023, Molecular pharmaceutics.

Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy

R. Schibli, P. Grundler, P. Bernhardt, 2023, The Journal of Nuclear Medicine.

Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy.

F. Borgna, R. Schibli, C. Müller, 2022, Molecular pharmaceutics.